If you’ve been following our coverage of Orexigen’s obesity drug, Contrave, you’re likely aware that it has been through a regulatory rollercoaster over the past few...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
30 readers recommended
Does how often you eat make your blood glucose worse? CDE Gary Scheiner explains…
41 readers recommended
Earlier in April, Biodel management updated the timeline for the development of its ultra-rapid-acting insulin candidates. As a reminder, in October 2010 the company's...
26 readers recommended
In late July, pharmacy benefit managers (PBMs) Express Scripts and Medco Health Solutions announced their plans to merge. As background, PBMs process prescriptions for...
39 readers recommended
In late June, the European Medicines Agency (EMA) approved Amylin/Eli Lilly/Alkermes’ once-weekly injectable drug Bydureon for type 2 diabetes. We’ve been waiting for...
43 readers recommended
In October, Novo Nordisk announced that it had submitted its two new “next-generation” insulin products for approval in both the US and Europe (and Japan to follow soon...
50 readers recommended
In June, Insulet announced the acquisition of Neighborhood Diabetes, a medical equipment distributor that specializes in consumer sales of diabetes supplies. The company...
59 readers recommended
Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...
37 readers recommended
In previous issues, we’ve documented the arduous journey of Orexigen’s anti-obesity drug Contrave through the regulatory process. In December, an FDA Advisory Committee...
21 readers recommended
What are going to be the big headlines for 2012? What will be the impact of Bydureon, the latest once-weekly drug for people with type 2 diabetes?
38 readers recommended
On June 16, FDA officials provided an update on its safety review of Takeda’s Actos (pioglitazone), announcing that going forward, prescribing information for Actos will...
47 readers recommended
On January 27, the Food and Drug Administration (FDA) granted approval to Bydureon, a new drug for type 2 diabetes that is injected once a week. Approved last year in...
22 readers recommended
Kelly’s take on the maddeningly slow FDA approval process and why things are probably getting better.
29 readers recommended
Kerri Morrone Sparling reflects on the true meaning of ‘need’ in the global diabetes community…
38 readers recommended
Novo Nordisk’s Head of China Ron Christie divulges details on the state of diabetes care in the world’s most populous nation.
39 readers recommended
As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...
29 readers recommended
Late last year, we found out about a new drug being developed by Reata Pharmaceuticals for the treatment of chronic kidney disease (CKD), a disorder that occurs more...
48 readers recommended
While Lantus (Sanofi’s insulin glargine) is the current standard for basal insulins, companies are still investing significant efforts to develop even better long-acting...
34 readers recommended
At EASD, Cellnovo announced that it had received approval in Europe for its new insulin patch pump. It will be launched soon in the UK, and its submission to the FDA is...
56 readers recommended
Want faster acting insulin? CDE Gary Scheiner shows you some options with five innovative tips that you may want to consider…